Skip to main content

Rani Therapeutics Holdings, Inc. (RANI)

NASDAQ: RANI · Delayed Price · USD
19.30 0.48 (2.55%)
Sep 21, 2021 4:00 PM EDT - Market closed
Market Cap956.52M
Revenue (ttm)1.14M
Net Income (ttm)-16.95M
Shares Out49.56M
EPS (ttm)-0.34
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Close18.82
Day's Range18.63 - 19.70
52-Week Range9.24 - 29.40
Price Target24.60 (+27.5%)
Est. Earnings DateNov 15, 2021

About RANI

Rani Therapeutics is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics. We have developed the RaniPill capsule, which is our novel, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill approximately the size of a “000” capsule (or similar to the size of a standard fish oil or calcium pill) that is designed to automatically administer a precise ther...

IPO DateJul 30, 2021
CEOTalat Imran
Stock ExchangeNASDAQ
Ticker SymbolRANI
Full Company Profile

Financial Performance

In 2020, RANI's revenue was $462,000, a decrease of -52.81% compared to the previous year's $979,000. Losses were -$16.70 million, -37.18% less than in 2019.

Financial Statements


Rani Therapeutics Reports Second Quarter 2021 Financial Results, Provides Corporate Update

- IPO in July 2021 raised $84.3 million in gross proceeds - - Talat Imran Appointed Chief Executive Officer - - Enhanced leadership team with key management and board of directors' appointments -

1 week ago - GlobeNewsWire

Wednesday Afternoon Analyst Upgrades and Downgrades: Applied Materials, Best Buy, Intuit, Medtronic, Toll Brothers an...

The markets were higher across the board near midday, after a strong two-day rally opened the trading week.

3 weeks ago - 24/7 Wall Street

Rani Therapeutics, RxSight: 2 Bullish Health Care Stock Picks From BofA

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), an early stage platform technology company that promotes oral dosing with its RaniPill, and RxSight, Inc. (NASDAQ:RXST), an ophthalmology-focused MedTech ...

Other symbols:RXST
4 weeks ago - Benzinga

Rani Therapeutics Announces Closing of its Initial Public Offering and Full Exercise of Underwriters' Option to Purch...

SAN JOSE, Calif., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq:RANI) (“Rani Therapeutics” or “Rani”), a clinical stage biotherapeutics company focused on advancing technolo...

1 month ago - GlobeNewsWire

Rani Therapeutics' $73M IPO will fund upcoming clinical trials

Rani Therapeutics, a San Jose-based company developing a pill to replace medical injections, went public on Friday.  According to S-1 filings, shares were estimated to price between $14 and $16 last week.

1 month ago - TechCrunch

Rani Therapeutics Debuts On The Nasdaq: What You Should Know About The Biopharma

Rani Therapeutics Holdings, Inc. (NASDAQ: RANI), a San Jose, California-based early stage biopharma, debuted Friday on the Nasdaq in its initial public offering. Rani Shares Trade Around IPO Price: Rani...

1 month ago - Benzinga

Rani Therapeutics Announces Pricing of Initial Public Offering

SAN JOSE, Calif., July 30, 2021 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”), a clinical stage biotherapeutics company focused on advancing technologies to enable...

1 month ago - GlobeNewsWire

2 more biotech companies, backed by industry pioneers, plot IPOs

One company was launched by the venture capital firm led by Genentech's first scientist; the other by an inventor of an early defibrillator.

2 months ago - San Francisco Business Times

Rani Therapeutics IPO Registration Document (S-1)

Rani Therapeutics Holdings, Inc. has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC